BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 7819706)

  • 1. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
    J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009154. PubMed ID: 26148507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
    Herman A; Raziel A; Strassburger D; Soffer Y; Bukovsky I; Ron-El R
    Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteal phase support and severe ovarian hyperstimulation syndrome.
    McClure N; Leya J; Radwanska E; Rawlins R; Haning RV
    Hum Reprod; 1992 Jul; 7(6):758-64. PubMed ID: 1500471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
    Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
    Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P; Domingo M; Leader A
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A; Fulghesu AM; Villa P; Guida C; Guido M; Nicoletti MC; Caruso A; Mancuso S
    Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.